In Acute Myeloid Leukemia (AML), FLT3 is a commonly observed, acquired genetic mutation that plays a significant role in the disease's pathogenesis. The positivity of FLT3 in AML holds two primary significances:
1. The presence of an FLT3 mutation places the patient in a high-risk group. In this scenario, evaluation for stem cell transplantation candidacy is generally required as part of the treatment plan.
2. Currently, targeted therapies (smart drugs) that specifically aim at the FLT3 mutation are available. These drugs are used in addition to standard chemotherapy, both in first-line treatment and in subsequent consolidation/maintenance therapies, with the goal of mitigating the mutation's effects.